康弘药业米拉贝隆缓释片获批上市

Core Viewpoint - Kanghong Pharmaceutical has received the drug registration certificate for Mirabegron extended-release tablets from the National Medical Products Administration, marking a significant milestone for the company in the treatment of overactive bladder (OAB) [1] Company Summary - The approved drug, Mirabegron, is a selective β3 adrenergic receptor agonist that relaxes the bladder smooth muscle [1] - The indication for this approval is for the symptomatic treatment of adult patients with overactive bladder, specifically addressing symptoms such as urgency, frequency, and/or urge incontinence [1]